MaxCyte, Inc.
MXCT
NASDAQ·Healthcare·Biotechnology·Mkt cap $137.1M
$1.28
▲ +1.59%
P/E
-3.77
Mkt Cap
$137.1M
52-Wk Range
$0.64–$1.87
52-Week Range
$0.64 - $1.87
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 9.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary flow electroporation technology enabling scalable cell engineering
- Recurring revenue model through disposable consumables and processing assemblies
- Established relationships with leading pharmaceutical and biotech companies
- Scalable platform spanning research to commercial manufacturing applications
- Intellectual property portfolio protecting core electroporation technologies
Bear Case
1 risk
- Above-average volatility (beta 1.5).
Growth
Stable outlook
Expansion of cell and gene therapy market adoption and commercialization
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Strong
+11.3% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying MXCT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 12, 2026
Reported EPS of -$0.08 vs -$0.09 consensus (+11.1% surprise). Revenue of $7.3M vs $6.5M expected (+11.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+11.1%
Revenue trend · last 8Q
—
-45%
-8%
-18%
-16%
-16%
-7%
-15%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$8.2M
$8.7M
$10.4M
$8.5M
$6.8M
$7.3M
$9.7M
$7.3M
Margins · last 8Q
Gross
90.9%
Operating
-113.6%
Profit
-122.0%
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: BTIG · Aug 24, 2026
vs Industry
How MXCT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related